On this page
Quick Reference
Overview and Recommendations
Background
- • (PG) is a rare neutrophilic dermatosis causing rapidly progressive, intensely painful, sterile cutaneous ulceration. Classic lesions have a necrotic base and reddish-violaceous, undermined borders; minor trauma may enlarge them through .
- •PG is noninfectious, although open ulcers can develop colonization or secondary infection. A positive wound culture does not by itself exclude PG; in one cohort, bacterial growth occurred in 50.3% of PG ulcers and the organisms did not distinguish them from venous ulcers.
- •Recognize PG as a , not a diagnosis established by a pathognomonic biopsy. Histology may show dermal neutrophilic inflammation, necrosis, and ulceration, but findings are variable and nonspecific; biopsy chiefly helps exclude infection, , malignancy, and other ulcerative disorders.
- •Classic ulcerative PG is the prototypic phenotype, but bullous, pustular, vegetative, peristomal, postoperative, and genital forms occur. Phenotypes may overlap or evolve, so classify the morphology while correlating it with lesion tempo, comorbidity, microbiology, and histology when needed.
- •PG commonly occurs without an identifiable systemic disorder, but approximately 50%-70% of patients in some series have an associated condition. Ask about , inflammatory arthritis, hematologic disease, and childhood-onset autoinflammatory syndromes; an initially negative history does not end longitudinal surveillance.
Evaluation
- •Assess the lesion’s trajectory from its initial tender papule, pustule, or nodule through rapid ulceration. Severe pain, rapid progression, necrosis, an irregular reddish-violaceous or gunmetal border, and undermining strongly support PG, but none is pathognomonic.
- •Examine the entire lesion and surrounding skin for new ulcers, active undermining, erythema, drainage, exposed tendon or muscle, and pathergy at sites of biopsy, venipuncture, surgery, injections, appliance changes, or other trauma. Document distribution; lower legs are most common, but PG can occur at any cutaneous site.
- •Treat fever, malaise, leukocytosis, and elevated inflammatory markers as nonspecific. Assess the clinical trajectory, because antibiotics and source-control procedures may fail to halt sterile inflammation while repeated trauma can accelerate it.
- •For postoperative or peristomal lesions, evaluate urgently for infection while considering PG. Wound separation, necrosis, purulent discharge, severe pain, extension beyond an incision or stoma, or worsening after debridement should prompt dermatology and surgical reassessment.
- •Obtain a with differential and review the peripheral smear. Measure and/or , electrolytes, glucose, albumin, liver enzymes, bilirubin, and renal function to establish inflammatory and treatment-risk baselines.
- •Ask about diarrhea, rectal bleeding, abdominal pain, weight loss, perianal disease, and prior bowel surgery. Ask about inflammatory back pain, synovitis, prolonged morning stiffness, enthesitis, dactylitis, and episodic arthritis; arrange gastroenterology or rheumatology assessment when findings support associated disease.
- •Consider hematologic assessment for bullous or atypical PG, unexplained cytopenias, abnormal smear findings, constitutional symptoms, recurrent disease, or known myeloid disease. Review for myelodysplastic syndrome, leukemia, lymphoma, myeloproliferative disease, and when the clinical context warrants it.
- •Order targeted studies for when lesions are palpable or retiform purpura, acral or multifocal, or accompanied by renal, pulmonary, neurologic, ocular, or constitutional findings. Use vascular studies, including ankle-brachial index or toe pressures and arterial or venous , when ischemia or venous disease is plausible.
- •Use an incisional or punch through the active ulcer edge into adjacent normal-appearing skin when morphology is atypical, infection is plausible, or vasculitis or malignancy cannot be excluded. Add base tissue and coordinate routine histology with bacterial, fungal, and mycobacterial studies when deep infection, an infiltrative process, or malignancy is suspected; explain pathergy risk before sampling.
- •Interpret histology as primarily exclusionary. A nondiagnostic biopsy does not exclude PG, while organisms, vasculitis, atypical cells, or an unexpected infiltrate should redirect the workup before immunosuppression.
- •Use deep tissue or properly collected wound specimens when infection is clinically suspected rather than relying on a superficial swab. Culture positivity may indicate colonization or secondary infection; treat infection when clinical, microbiologic, histologic, or imaging findings support invasion.
- •Apply structured diagnostic reasoning rather than relying on one finding. The 2018 Delphi framework requires one major criterion plus at least four minor criteria, while emphasizes progressive disease, a reddish-violaceous border, and reasonable exclusion of other diagnoses; a score of 10 or more has traditionally supported PG, but does not eliminate infection, vascular disease, malignancy, or mixed pathology.
Management
- •Use local treatment only when disease is limited, superficial, nonprogressive, and located where atraumatic care will not jeopardize function. Reassess frequently and escalate when new ulcers, advancing undermining, substantial depth, severe functional impairment, extracutaneous disease, or systemic inflammation develops.
- •Cleanse gently with lukewarm saline or water without rubbing the active border. Apply a nonadherent contact layer, such as petrolatum-impregnated gauze or a soft silicone interface, with an absorbent secondary dressing; maintain a moist rather than macerated or desiccated environment.
- •Avoid hydrogen peroxide, hypochlorite, iodine, and other caustic antiseptics on the active ulcer unless a wound specialist has a specific, time-limited indication. Secure dressings without adhesive across the ulcer edge, remove them slowly after moistening, and avoid repeated manipulation.
- •For limited superficial inflammation, a potent topical corticosteroid such as may be applied to the active edge and surrounding skin under dermatology direction. is a steroid-sparing option for thin skin, near an ostomy, or when corticosteroid atrophy is a concern; evidence does not establish an optimal dose, frequency, or monotherapy regimen.
- •Treat pain before dressing changes. Use an ulcer-compatible topical anesthetic according to product labeling and add systemic analgesia when needed; record pain on a reproducible 0-10 scale and address sleep, mobility, nutrition, mood, and dressing tolerance.
- •Control edema and venous hypertension only after confirming adequate arterial supply and at a tolerable compression level. Elevate the limb, mobilize when feasible, protect the periwound skin, and manage peristomal leakage, friction, and appliance trauma with an experienced ostomy and wound-care team.
- •Start systemic therapy for rapidly enlarging, painful, deep, multifocal, function-threatening, extracutaneous, or substantially inflammatory disease. Reassess progression, pain, ulcer area, depth, and new lesions at least weekly during induction; the first goals are cessation of enlargement and new lesions, followed by reduced pain and undermining and then epithelial advancement.
- •For severe active disease, use 20-40 mg orally once daily, approximately 0.6-0.8 mg/kg/day, maintaining the starting dose until enlargement and inflammatory edge activity have clearly stopped, usually for 2-4 weeks, then taper slowly according to response. Avoid prolonged high-dose corticosteroid monotherapy and monitor glucose, blood pressure, infection, mood, myopathy, bone risk, and adrenal suppression.
- •Use 3-5 mg/kg/day orally in two divided doses when rapid steroid-sparing control is needed, particularly with diabetes, severe steroid toxicity, or a corticosteroid contraindication. Check creatinine/eGFR, urea, potassium, magnesium, liver tests, blood pressure, and drug interactions at baseline and at least every 1-2 weeks during dose adjustment, then monthly when stable; avoid it in uncontrolled infection, significant renal impairment, uncontrolled hypertension, or untreated malignancy risk.
- •For fulminant disease, unreliable oral absorption, or a threatened critical site, intravenous methylprednisolone commonly 500-1000 mg intravenously once daily for 3 consecutive days can be used, although PG-specific comparative evidence for pulse therapy is weak. Choose prednisone or cyclosporine by comorbidity and toxicity rather than assuming a difference in efficacy.
- •Add a steroid-sparing agent before repeated high-dose corticosteroid courses when disease relapses during tapering. Options include 500 mg orally twice daily, increasing over 1-2 weeks to 1-1.5 g twice daily if tolerated; 15-25 mg orally or subcutaneously once weekly with folic acid; or 1-2.5 mg/kg orally once daily, with monitoring and reproductive-risk review.
- •Consider when rapid biologic treatment is needed, particularly with inflammatory bowel disease or inflammatory arthritis. Use 5 mg/kg intravenously at weeks 0, 2, and 6, then every 8 weeks when ongoing suppression is required; screen for tuberculosis and hepatitis B, review infection risk, and assess for heart failure and demyelinating disease.
- •Use when outpatient self-administration or treatment of inflammatory bowel disease or arthritis favors a subcutaneous agent: 160 mg subcutaneously at week 0, 80 mg at week 2, then 40 mg every 2 weeks. Before anti-TNF therapy, perform symptom-directed infection assessment, tuberculosis evaluation, hepatitis B testing, CBC, liver tests, and vaccination review; do not start during uncontrolled serious infection and avoid live vaccines during therapy.
- •Reserve intravenous immunoglobulin, ustekinumab, anakinra, canakinumab, or IL-23 inhibition for refractory disease or selected comorbid and autoinflammatory contexts. Examples include intravenous immunoglobulin 2 g/kg divided over 2-5 days, approximately 6 mg/kg intravenously once followed by 90 mg subcutaneously at week 8 and every 8-12 weeks, 100 mg subcutaneously once daily, or 150 mg subcutaneously every 8 weeks; evidence is mainly observational or case-based.
- •Do not present IL-17 or IL-23 inhibition as established first-line PG treatment. IL-17 blockade can aggravate or destabilize inflammatory bowel disease; selective IL-23 inhibition may be considered after conventional-treatment failure, such as 100 mg subcutaneously at weeks 0 and 4 then every 8 weeks, with explicit recognition that treatment is off-label for PG.
- •Avoid routine aggressive debridement, wide excision, and primary closure while the border is active or the diagnosis remains uncertain. Use gentle cleansing and selective removal of loose necrotic material; operate only for demonstrable source control, deep or prosthetic infection, sepsis, compartment or limb threat, uncontrolled hemorrhage, or threatened function, removing no more tissue than necessary.
- •Defer , , biologic matrix, and reconstructive revision until inflammation is controlled, the wound is stable and adequately perfused, and a perioperative immunosuppressive plan is in place. Minimize incision, shear, adhesive, donor-site, and dressing trauma, and monitor incision, drain, graft, and venipuncture sites for pathergy.
- •Continue immunosuppression until control is durable: no enlargement or new lesions, settled edge inflammation, sustained pain improvement, and progressive epithelial advancement. Taper deliberately rather than abruptly, record wound area, depth, photographs, pain, function, treatment toxicity, and associated-organ disease, and educate patients to report renewed pain, pustulation, violaceous undermining, or a new ulcer promptly.
Deep Dive — Evidence Details
Definition, Nosology, and Clinical Identity
- ▸Rapid painful ulceration plus a violaceous undermined border is the prototypic pattern.
- ▸Avoid reflexive debridement; culture positivity may represent colonization or secondary infection.
Core diagnosis
(PG) is a rare causing rapidly progressive, intensely painful, sterile ulceration with necrosis and a reddish-violaceous, undermined border. means trauma can enlarge lesions. The name is misleading: secondary microbial growth may occur, but a positive culture does not prove primary infection. [2][4][5][7]
PG is a ; biopsy findings are variable and nonspecific, so biopsy mainly excludes infection, , malignancy, and other ulcers. Related disorders include , , and , but neutrophils alone do not establish PG. Clinical variants include classic ulcerative, bullous, pustular, and vegetative PG. [1][2][5][12][19]
Pearl: PG is best recognized as a clinical pattern of sterile, neutrophil-mediated ulceration whose diagnosis depends on the whole trajectory of the lesion and the disciplined exclusion of mimics, not on the word “pyoderma,” a positive culture from a chronic wound, or neutrophilic inflammation in isolation. [2][4]
Innate Immune Dysregulation and Pathogenesis
- ▸IL-1, IL-8, and TNF recruit and activate tissue-damaging neutrophils.
- ▸Pathergy is biologically central; surgery and debridement can worsen disease.
Mechanism
PG reflects dysregulated innate immunity rather than invasive infection. Tissue injury activates myeloid cells through NF-κB and inflammasome pathways, increasing IL-1β, TNF, and chemokines such as IL-8. These mediators recruit neutrophils, which release proteases, reactive oxygen species, and extracellular chromatin structures that damage tissue and impair repair. New danger signals then reactivate myeloid cells, producing a self-amplifying cycle. [21][23]
TNF-dependent cell death and impaired inflammasome suppression were demonstrated in OTULIN-R57C disease; rare PSTPIP1, MEFV, and OTULIN abnormalities establish genetic plausibility but explain only a minority of cases. IL-23/IL-17 may sustain selected disease states; evidence is less mature and computational or retrospective. [21][22][25]
Pathergy results when trauma fails to resolve and instead amplifies inflammation. Ulcer cultures may be positive in 50.3% of cases, similar to venous ulcers; interpret organisms as colonization or secondary infection unless invasion is supported. [4][7][17]
Pearl: PG behaves as a self-amplifying wound-inflammation circuit: myeloid activation and inflammasome signaling generate IL-1, IL-8, and TNF; these recruit and activate neutrophils, with IL-23/IL-17 signaling potentially sustaining selected disease states; trauma and debridement can feed the circuit, and microbial growth may be a passenger rather than the driver.
Epidemiology, Associations, and Risk Context
- ▸Ask specifically about bowel symptoms, inflammatory arthritis, cytopenias, constitutional symptoms, and early-onset autoinflammation.
- ▸A negative systemic history at presentation does not eliminate later association.
Who develops PG
Incidence is approximately 3-10 cases per million people per year. PG can occur at any age but most often begins at 30-55 years; women are slightly more affected. About 50%-70% of some cohorts have a systemic association, but many patients are sporadic and the associated disease may appear later. [5][33][34]
Important associations are (Crohn disease or ), , seronegative , hematologic malignancy or , leukemia, lymphoma, myeloproliferative disease, and occasional . In one series, IBD occurred in 21.8%, rheumatoid arthritis in 15.6%, and seronegative spondyloarthritis in 9.4%. Bullous PG particularly suggests myeloid disease. [17][19][33]
Childhood or adolescent onset with sterile arthritis, acne, hidradenitis, or family history suggests PAPA/PASH-spectrum disease involving . Surgery, stomas, injections, and biologics are risk contexts, not diagnoses. [27][35][38]
Pearl: PG is most often an adult disorder with a female predominance, but the patient’s age, inflammatory bowel or joint history, hematologic clues, and timing around trauma or surgery materially change the probability of an associated systemic disease. [5][17][19][33]
Clinical Presentation
- ▸The border and trajectory are more informative than purulence or culture results.
- ▸Postoperative and peristomal PG commonly mimics infection or dermatitis.
Recognizing the lesion
PG often begins as a tender papule, pustule, or nodule and ulcerates within hours to days. The active ulcer is usually severely painful, necrotic, and exudative, with an irregular reddish-violaceous or gunmetal, undermined border. Purulence, fever, leukocytosis, and elevated inflammatory markers may occur but do not distinguish PG from infection. [4][5][30][45]
Lower legs are most common, but thighs, abdomen, trunk, upper limbs, genital skin, postoperative wounds, and peristomal sites may be involved. In one series, 86.4% had lower-extremity disease and 25.9% trunk involvement. New lesions after biopsy, venipuncture, surgery, injection, appliance changes, or minor trauma strongly suggest . [7][17][33]
Healing occurs by edge re-epithelialization and may leave a thin, cribriform, atrophic “wrinkled-paper” scar. Failure of antibiotics or worsening after debridement should trigger reassessment, while documented secondary infection still requires treatment. [2][7]
Pearl: Severe pain, rapid progression, an irregular ulcer, and a violaceous border are useful diagnostic clues, but none is pathognomonic and the principal mimics still require exclusion [5].
Recognizable Phenotypes and Variants
- ▸Bullous PG warrants hematologic review; pustular PG warrants assessment of IBD activity.
- ▸Peristomal and postoperative lesions require aggressive trauma avoidance.
Clinical variants
Classic ulcerative PG is rapidly progressive and deeply painful. Bullous or atypical PG causes superficial hemorrhagic bullae and is particularly associated with , , and other myeloid disease. Pustular PG may accompany an flare. Vegetative PG is indolent, shallow, verrucous or granulomatous, and often has limited systemic inflammation. [5][12][19]
Peristomal PG accounts for approximately 15% of cases and worsens with leakage, appliance trauma, or debridement. Postoperative PG causes erythema, bullae, necrosis, wound separation, and purulence beyond an incision. Genital PG may mimic sexually transmitted infection, Fournier gangrene, or Crohn-related disease. Extracutaneous neutrophilic disease is rare and may involve eye, bone, lung, liver, or spleen. [28][40]
Variants can coexist or evolve; morphology should be reassessed whenever disease changes. A neutrophilic biopsy alone does not distinguish PG from , , or other neutrophilic disorders. [1][2]
Pearl: A phenotype is a diagnostic clue, not a substitute for clinicopathologic correlation and exclusion of its mimics.
Diagnosis: Delphi, PARACELSUS, and Differential
- ▸PARACELSUS is more sensitive and usable when biopsy is deferred because of pathergy.
- ▸A high score supports but does not eliminate dangerous mimics.
Structured diagnosis
The 2018 Delphi criteria require one major criterion, ulcer-edge biopsy showing neutrophilic infiltrate, plus at least four minor criteria: infection exclusion, pathergy, papule/pustule/vesicle ulcerating within 4 days, undermined tender erythematous border, multiple ulcers including an anterior lower-leg ulcer, cribriform scars, and improvement within 1 month of immunosuppression. In a retrospective cohort, sensitivity was 19% and specificity 100%; only 7/26 biopsies met the major criterion. [2]
PARACELSUS emphasizes progressive disease, reddish-violaceous border, and absence of a more likely diagnosis (3 points each), plus pain >4/10, pathergy, immunosuppressive response (2 each), preceding lesion, multiplicity, cribriform scar, and undermining (1 each). Traditionally, ≥10 supports PG. In 1,403 wounds, >10 gave sensitivity 98.3%, specificity 96.8%, and PPV 81.9%; ≥10 had sensitivity 100.0%, specificity 93.2%, PPV 68.4%. [3]
Su criteria are more specific but less sensitive. Always exclude infection, vascular occlusion, vasculitis, calciphylaxis, malignancy, and factitial disease.
Pearl: Diagnose PG by convergence: characteristic evolution and border, deliberate exclusion of competing mechanisms, judicious use of biopsy, and longitudinal behavior. Neither neutrophils, negative cultures, a high score, nor treatment response can carry the diagnosis alone.
Biopsy, Microbiology, and Systemic Evaluation
- ▸Limit biopsy and debridement to clinically necessary sampling because trauma can worsen PG.
- ▸Systemic evaluation should be hypothesis-driven, not an indiscriminate panel.
Practical workup
Biopsy when morphology is atypical, infection is plausible, or or cannot be excluded; discuss first. Sample the active ulcer edge into adjacent normal skin, with additional base tissue for deep infection or infiltrative disease. Send routine histology plus bacterial, fungal, and mycobacterial studies when indicated. Histology is mainly exclusionary; only 10/26 biopsies were contributory in one cohort, and a nondiagnostic biopsy does not exclude PG. [2][51]
Use deep tissue rather than superficial swabs when infection is suspected. Obtain CBC with differential and smear, CRP/ESR, electrolytes, glucose, albumin, liver and renal tests. Ask about diarrhea, rectal bleeding, arthritis, inflammatory back pain, cytopenias, constitutional symptoms, and recurrent infections. Target urinalysis, vascular studies, paraprotein testing, gastrointestinal evaluation, rheumatology, hematology, or immunology to the phenotype. [19]
Repeatedly positive cultures may represent colonization; bacterial growth occurred in 50.3% of PG ulcers. [4]
Pearl: Biopsy is most valuable for excluding infection, vasculitis, malignancy, or another ulcerative disorder; its greatest contribution is often identifying an alternative disease rather than proving PG.
Severity and Treatment Response
- ▸New ulcers indicate ongoing activity even if the largest ulcer is shrinking.
- ▸Pain and function are core outcomes, not optional adjuncts.
Measure more than area
There is no universally validated staging system. Record ulcer number, maximum and cumulative area, depth, exposed structures, progression rate, anatomic risk, pain, function, quality of life, pathergy, systemic inflammation, and associated-organ disease. Large disease means ≥64 cm² or exposed tendon/muscle in one cohort and predicts slower healing and recurrence. [18]
Use calibrated planimetry or consistent length×width measurements and standardized photographs. The supports diagnosis, not severity. The and (ClinPRO) may structure follow-up, but 17/20 published instruments lacked validation. had ICC 0.76 in 36 patients. [3][60][62][63]
Response is sequential: enlargement stops, pain falls, undermining resolves, granulation appears, and epithelium advances. Reduced erythema alone is inadequate. [59][60][69]
Pearl: Follow PG with a wound map, calibrated area measurements, photographs, pain and function scores, and associated-organ assessment; call it response only when progression and pain have stopped and repair is demonstrable, not when erythema merely looks less intense.
Local Control of Limited PG
- ▸Protect the active edge from friction, adhesive stripping, chemical injury, and repeated manipulation.
- ▸Topical therapy must not delay systemic treatment for progressive disease.
Atraumatic wound care
Local therapy is reasonable for limited, superficial, nonprogressive disease without systemic involvement; evidence is observational and no randomized trials establish topical monotherapy. [75] Clean gently with saline or water, avoid rubbing, use nonadherent or soft-silicone contact layers, maintain a moist but nonmacerated environment, and secure dressings without adhesive on the edge. Avoid peroxide, hypochlorite, iodine, and caustic antiseptics. [40][71]
A potent topical corticosteroid such as clobetasol may be applied to the active edge; topical tacrolimus is a steroid-sparing option for thin skin or prolonged treatment. Intralesional corticosteroid is reserved for a few small lesions because injection can cause pathergy. Treat pain before dressing changes; use ulcer-compatible topical anesthetic and systemic analgesia as needed. Compression is appropriate only after adequate arterial supply is confirmed. Peristomal care requires leak prevention and minimal appliance trauma. [71][75][79]
Escalate for progression, depth, severe pain, new ulcers, or systemic inflammation.
Pearl: Local treatment is reasonable when disease is limited, superficial, nonprogressive, and confined to anatomy where local care can be delivered without jeopardizing function; early or mild disease and idiopathic PG are the populations in which topical monotherapy has been proposed. [75]
Systemic Immunosuppression and Biologic Therapy
- ▸Prednisone and cyclosporine are rapid options; selection depends mainly on comorbidity and toxicity.
- ▸Infliximab is the best-supported biologic, especially with IBD or inflammatory arthritis.
Indications and regimens
Systemic treatment is needed for rapidly enlarging, painful, deep, multifocal, function-threatening, extracutaneous, or highly inflammatory disease. Reassess weekly during induction. Evidence is limited: only two randomized trials were identified among 41 studies. [91]
20-40 mg/day (approximately 0.6-0.8 mg/kg/day) is rapid induction; taper slowly after 2-4 weeks of clear control. IV methylprednisolone 500-1000 mg/day for 3 days is reserved for fulminant disease. 3-5 mg/kg/day in divided doses is an alternative or steroid-sparing option; monitor creatinine, electrolytes, liver tests, blood pressure, and interactions. STOP-GAP found similar healing: 15-20% at 6 weeks and 47% at 6 months. [69][91]
For refractory or IBD-associated disease, 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks has the strongest biologic evidence; 46% improved at 2 weeks versus 6% placebo. uses 160 mg week 0, 80 mg week 2, then 40 mg every 2 weeks. Screen TB/hepatitis and avoid uncontrolled infection. [29][91]
Pearl: Choose the fastest effective immunosuppression for the trajectory of the ulcer, but let IBD, arthritis, hematologic disease, infection risk, renal function, pregnancy potential, malignancy history, and cumulative toxicity determine which agent carries the patient safely to durable control.
Surgery, Debridement, and Reconstruction
- ▸Worsening after debridement may represent pathergy rather than inadequate source control.
- ▸Reconstruction should be delayed until sustained inflammatory control.
Avoid pathergy
Active PG changes surgery from source control to potential inflammatory amplification. Avoid routine aggressive debridement, wide excision, primary closure, and repeated traumatic dressing procedures while the border is active or diagnosis uncertain. [7][57]
Operate only for demonstrable deep infection, sepsis, prosthetic infection, compartment or limb threat, uncontrolled hemorrhage, or essential functional preservation. Obtain deep cultures when infection is plausible and remove no more tissue than required. Selective removal of loose necrotic material remains unresolved; evidence for or against it is lacking. [86]
Coordinate dermatology, surgery, infectious diseases, and relevant specialists. For elective reconstruction, wait until disease is quiescent, with no expanding ulcer or new pathergy. Negative-pressure wound therapy, split-thickness grafts, biologic matrices, and stoma revision are specialist options after inflammatory control; donor and recipient sites may both develop PG. [9][31][40][45][100]
Pearl: In PG, uncontrolled inflammation is usually the problem that surgery amplifies. Debride only for a defined infectious or functional emergency; otherwise suppress disease, protect tissue, and reconstruct after the border has become quiet. [57][45]
Pregnancy, Childhood, Peristomal, and Postoperative PG
- ▸Early-onset disease should prompt immune and autoinflammatory evaluation.
- ▸Peristomal and postoperative trauma can rapidly amplify disease.
High-risk settings
Childhood-onset or recurrent PG with sterile arthritis, acne, hidradenitis, infection susceptibility, family history, or poor wound healing warrants evaluation for inborn errors of immunity and autoinflammatory syndromes, including PAPA/PASH, MEFV- and OTULIN-related disease. Use phenotype-directed CBC, immune testing, and genetics with pediatric specialists. [27][99][104]
Pregnancy often involves delayed diagnosis; among 63 reported cases, 45 were initially misdiagnosed. Corticosteroids were used in 56 and cyclosporine in 21, but safety evidence is limited. Coordinate treatment with maternal-fetal medicine; corticosteroids, cyclosporine, selected anti-TNF therapy, and IVIG may be considered according to severity and reproductive risk. [103]
Peristomal PG requires leak control, barrier protection, atraumatic appliance changes, and systemic treatment when progressive. Postoperative PG requires parallel assessment for necrotizing infection while avoiding reflexive debridement. [40][57][30]
Pearl: In pregnancy, childhood, peristomal disease, and postoperative disease, diagnosis is often delayed because infection or wound failure is assumed; early multidisciplinary assessment and trauma avoidance are essential. [103][40][57]
Complications and Safety Problems
- ▸Culture positivity and chronic drainage do not independently establish invasive infection.
- ▸Balance immunosuppression against infection, renal, marrow, metabolic, and reproductive risks.
Monitor complications
Secondary infection is suggested by new spreading cellulitis, warmth, fever, rigors, bacteremia, hemodynamic instability, or tissue deterioration, not chronic exudate alone. Culture deep tissue and obtain blood cultures when systemic illness is present. Admit for sepsis, suspected necrotizing infection, uncontrolled pain, major bleeding, threatened function, deep infection, or inability to maintain nutrition. Image deep ulcers or those with exposed bone, hardware, focal tenderness, or reduced motion; MRI is preferred for osteomyelitis or deep soft-tissue disease. [4][7]
Monitor hemorrhage, anemia, contracture, lymphedema, malnutrition, venous thromboembolism, depression, and treatment toxicity. Systemic corticosteroids cause infection, hyperglycemia, hypertension, osteoporosis, myopathy, mood effects, and adrenal suppression. Cyclosporine causes renal dysfunction and hypertension; antimetabolites cause cytopenias, hepatic toxicity, and reproductive toxicity. Biologics require TB/hepatitis screening and infection surveillance. [29][92][114][115]
Pearl: Treat complications by mechanism: infection requires antimicrobial and sometimes surgical source control, while sterile inflammatory progression requires immunosuppression and trauma avoidance.
Healing, Recurrence, and Long-Term Follow-up
- ▸Recurrence is common and may occur at the original or a new site after closure.
- ▸Pain and new edge inflammation may precede obvious ulcer enlargement.
Longitudinal care
Healing depends on inflammatory control, not ulcer size alone. A 32-patient series reported median clinical remission of 19 months. Among 116 healed patients, 35% recurred; cumulative recurrence was 27% at 1 year and 41.3% at 5 years. Large disease (≥64 cm² or exposed tendon/muscle), pathergy, peristomal disease, delayed recognition, and associated inflammatory or hematologic disease may worsen prognosis. [18][33][48]
At every visit, map ulcers, measure area and depth, photograph consistently, assess pain, function, sleep, mobility, drainage, new lesions, and epithelial advancement. Renewed pain, pustulation, violaceous undermining, or expansion at a scar indicates relapse. Continue immunosuppression until durable control and taper deliberately; coordinate with gastroenterology, rheumatology, or hematology when associated disease is present. [35][59]
Provide written relapse instructions and minimize unnecessary trauma, injections, surgery, and appliance injury.
Pearl: Patients therefore need a relapse plan that treats new pain or inflammatory change at a scar as a reason for prompt review, not as an expected feature of healing.
References
- [1]
Vrooman E, Grant-Kels JM. “Neutrophilic Dermatoses.” Clinics in dermatology (2026). PMID: 42508548 ↗
Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [2]
Moore AM, Karch JL, Bradley KE et al.. “The utility of biopsy in pyoderma gangrenosum: a retrospective cohort study.” Skin health and disease (2026). PMID: 41923959 ↗
Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [3]
Moelleken M, Ortega-Loayza AG, Busch D et al.. “Validation of PARACELSUS score performance for the diagnosis of pyoderma gangrenosum: An international multicenter study with 1403 cases.” Journal of the American Academy of Dermatology (2026). PMID: 41785996 ↗
Journal Article, Multicenter Study, Validation Study, Observational StudyCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [4]
Stenger KS, Burger ES. “Secondary Microbial Infection in Pyoderma Gangrenosum: Comparable Rates to Venous Ulcers in a Retrospective Cohort.” Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society (2026). PMID: 42032443 ↗
Journal Article, Comparative StudyCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum, Complications and Safety Problems in Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [5]
Mirzaei M, Jafarzadeh A, Salehi S et al.. “Demographic and Clinical Insights Into Pyoderma Gangrenosum: A Retrospective Cross-Sectional Study From a Tertiary Care Hospital.” Health science reports (2026). PMID: 42005678 ↗
Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [6]
Pan J, Qian J, Li X et al.. “Pyoderma Gangrenosum with Pseudoepitheliomatous Hyperplasia Histopathologically Misdiagnosed as Squamous Cell Carcinoma: A Case Report and Brief Literature Review.” Clinical, cosmetic and investigational dermatology (2026). PMID: 42266764 ↗
Case Reports, Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [7]
Algarni AS. “Pyoderma gangrenosum following joint arthroplasty: a comprehensive review of clinical features, diagnosis, and management.” Postepy dermatologii i alergologii (2026). PMID: 42148339 ↗
Journal Article, ReviewCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings, Complications and Safety Problems in Pyoderma Gangrenosum - [8]
Vahabi SM, Heidari S, Farahmand Y et al.. “JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports.” Dermatology research and practice (2026). PMID: 42472066 ↗
Journal Article, ReviewCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Complications and Safety Problems in Pyoderma Gangrenosum - [9]
Moravenova V, Wilhelm R, Veeser J et al.. “Case Report: Localized neutrophilic dermatosis at a split-skin donor site during PD-1 blockade: a unique immune-related adverse event.” Frontiers in immunology (2026). PMID: 42459659 ↗
Case Reports, Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy - [10]
Yang A, Tan B, Murrell DF. “Neutrophilic Dermatosis and Pyoderma Gangrenosum: A Not-So-Sweet Adverse Reaction to Pembrolizumab.” The Australasian journal of dermatology (2026). PMID: 42068136 ↗
LetterCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity - [11]
Lo N, Dazé R. “Clinical evolution of atypical pyoderma gangrenosum in a patient with hemochromatosis.” Journal of osteopathic medicine (2026). PMID: 41762618 ↗
Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum - [12]
Huggins LK, Collins RG, Friedland MH et al.. “Clinicopathological Challenge: A Rapidly Progressive Bullous Ulcer in a Patient Receiving Gilteritinib.” International journal of dermatology (2026). PMID: 42262147 ↗
Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [13]
Obeid L, Altorok N, Gilbert N. “Successful Treatment of Bullous Pyoderma Gangrenosum With Dapsone.” American journal of therapeutics (2026). PMID: 41668257 ↗
Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [14]
Li M, Wang Z. “Disseminated pustular eruption: Pyoderma gangrenosum as a rare manifestation in antineutrophil cytoplasmic antibody-associated vasculitis.” Rheumatology and immunology research (2026). PMID: 42444726 ↗
Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [15]
Rahman S, Akuffo-Addo E, Geng R et al.. “Genital Pyoderma Gangrenosum: A Systematic Review of Reported Cases and Treatment Outcomes.” Journal of cutaneous medicine and surgery (2026). PMID: 42109214 ↗
LetterCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [16]
Ross KR, Shea M, Latour E et al.. “Prospective investigation of peristomal pyoderma gangrenosum.” The Journal of investigative dermatology (2025). PMID: 41453598 ↗
Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Measuring Severity and Treatment Response in Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings, Healing, Recurrence, and Long-Term Follow-up - [17]
Shi Y, Tang B, Qu T et al.. “Case Report: Pyoderma gangrenosum masquerading as skin and soft tissue infection preceding myelodysplastic syndrome.” Frontiers in medicine (2026). PMID: 42058424 ↗
Case Reports, Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, Healing, Recurrence, and Long-Term Follow-up - [18]
Jiang J, Wee E, Jobson D et al.. “Pyoderma Gangrenosum: Association of Ulcer Size With Clinical Characteristics and Healing Outcomes.” The Australasian journal of dermatology (2026). PMID: 42334049 ↗
Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Measuring Severity and Treatment Response in Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [19]
Nadarajah N, Ho Tiu C, Walton S. “Systemic associations of pyoderma gangrenosum: a systematic review.” Skin health and disease (2026). PMID: 42540042 ↗
Journal Article, ReviewCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [20]
Talanker MM, Basta AV, Do T et al.. “Multidisciplinary Approach to Complex Lower Extremity Limb Salvage in Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne (PAPA) Syndrome: A Case Report.” Microsurgery (2026). PMID: 41978233 ↗
Case Reports, Journal ArticleCited in: Pyoderma Gangrenosum: Definition, Nosology, and Clinical Identity, Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [21]
Swaminathan B, Gil HM, Bhattad S et al.. “Pyoderma gangrenosum caused by the molecular uncoupling of OTULIN catalytic activity and LUBAC binding.” Nature immunology (2026). PMID: 42297973 ↗
Journal Article, Case ReportsCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [22]
Yao H, Wu Y, Zhang R. “Integrative Multi-Omics Analysis and Computational Modeling Identifying Shared Inflammatory Pathways and JAK Inhibitor Targets in PG and IBD.” International journal of molecular sciences (2026). PMID: 42123319 ↗
Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum - [23]
Balan K, Elston DM. “IL-1-targeted therapy in dermatologic conditions.” Journal of the American Academy of Dermatology (2026). PMID: 42264383 ↗
Journal Article, ReviewCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [24]
Wollina U. “Selective IL-23 Inhibition in Pyoderma Gangrenosum: Promise, Questions, and Next Steps.” International journal of dermatology (2026). PMID: 42084608 ↗
Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum - [25]
Bettolini L, Maronese CA, Derlino F et al.. “Selective IL-23 Inhibition in Conventional Treatment-Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study.” International journal of dermatology (2026). PMID: 42001205 ↗
Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [26]
Kishimoto M, Kimura-Sashikawa M, Komine M. “Immunohistochemistry Revealed Distinct IL-36γ Localization Among Different Skin Diseases.” The Journal of dermatology (2026). PMID: 42076875 ↗
Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum - [27]
Wang M, Zhang P, Shen M. “A de novo heterozygous PSTPIP1 variant associated with PAPA syndrome: a Chinese case report and literature review.” Frontiers in genetics (2026). PMID: 42358432 ↗
Case Reports, Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [28]
Panne I, Matter M, Vosbeck J et al.. “Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor.” Frontiers in immunology (2026). PMID: 42375372 ↗
Case Reports, Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum - [29]
Yamamoto T, Tanizaki H, Yamasaki K et al.. “Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study.” Dermatology and therapy (2026). PMID: 42107018 ↗
Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum, Complications and Safety Problems in Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [30]
Aldarwish S, Schafmayer C, Hinz S. “Postoperative Pyoderma Gangrenosum: Rare Infection Mimic and Diagnostic Challenge - A Case Report.” Visceral medicine (2026). PMID: 41659199 ↗
Case Reports, Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings, Complications and Safety Problems in Pyoderma Gangrenosum - [31]
Sun S, Zhu M, Wen C. “Probable pyoderma gangrenosum complicated with cutaneous Aspergillus flavus infection: case report.” Frontiers in medicine (2026). PMID: 42100284 ↗
Case Reports, Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy - [32]
Siebrasse AM, Kimpston CN, Haydek CG et al.. “Inflamed Skin and Bones: SAPHO Syndrome in a Patient with Indeterminate Colitis.” Digestive diseases and sciences (2026). PMID: 42010070 ↗
Journal ArticleCited in: Innate Immune Dysregulation and Pathogenesis of Pyoderma Gangrenosum, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum - [33]
Ramos-Rincón JM, Esteban-Jarabo J, Senent M et al.. “Pyoderma Gangrenosum in Spain: Clinical Features, Therapeutic Management, and Outcomes in a 32-Patient Case Series.” Health science reports (2025). PMID: 41424671 ↗
Journal ArticleCited in: Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context, Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Local Control of Limited Pyoderma Gangrenosum, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, Healing, Recurrence, and Long-Term Follow-up - [34]
Michelucci A, Capodici A, Granieri G et al.. “Trend in the Diagnosis of Pyoderma Gangrenosum in Italy: A Multicenter Study.” Dermatology (Basel, Switzerland) (2025). PMID: 41362186 ↗
Journal Article, Multicenter StudyCited in: Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context - [35]
Guse J, Blesl A, Esters P et al.. “International collaborative experiences in managing pyoderma gangrenosum in patients with inflammatory bowel disease.” Therapeutic advances in gastroenterology (2026). PMID: 42389209 ↗
Case Reports, Journal ArticleCited in: Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, Complications and Safety Problems in Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [36]
Ailawadi S, Sethi S, Mahmood A et al.. “Extraintestinal Cutaneous Manifestations in Inflammatory Bowel Disease Among Non-White Patients: A Retrospective Multicenter Study.” Journal of clinical gastroenterology (2026). PMID: 41564030 ↗
Journal ArticleCited in: Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis - [37]
Colman RJ, Vuyyuru SK, Solitano V et al.. “Incidence and prevalence of immune-mediated extraintestinal manifestations in pediatric inflammatory bowel disease: a systematic review and meta-analysis.” Crohn's & colitis 360 (2026). PMID: 42027410 ↗
Journal ArticleCited in: Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context - [38]
Woods RH. “Disproportionality analysis of pyoderma gangrenosum reporting to the FDA Adverse Event Reporting System in association with antirheumatic biologics.” Clinical rheumatology (2026). PMID: 42310248 ↗
Journal ArticleCited in: Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum, Complications and Safety Problems in Pyoderma Gangrenosum - [39]
Ye H, Patel JD, Mohammad AP et al.. “Generalized Pustular Psoriasis Confers Increased Risk of Pyoderma Gangrenosum: First Population-Based Evidence.” Dermatology (Basel, Switzerland) (2025). PMID: 41379726 ↗
Journal ArticleCited in: Who Develops Pyoderma Gangrenosum: Epidemiology, Associations, and Risk Context - [40]
Chen G, Lan X, Li F et al.. “Peristomal pyoderma gangrenosum: a review of nursing research progress.” Frontiers in medicine (2026). PMID: 41919168 ↗
Journal Article, ReviewCited in: Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Local Control of Limited Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings, Complications and Safety Problems in Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [41]
Becker SL, Zhang R, Latour E et al.. “Lesional pruritus in pyoderma gangrenosum: Present but not predominant.” JID innovations : skin science from molecules to population health (2026). PMID: 42472079 ↗
Journal ArticleCited in: Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [42]
Pang X, Tan L, Zhao B et al.. “Successful treatment of refractory and recurrent pyoderma gangrenosum with pustules and ulcers using spesolimab.” Clinical and experimental dermatology (2026). PMID: 41208349 ↗
Journal ArticleCited in: Clinical Presentation: Lesion Evolution, Distribution, and Symptoms - [43]
Kohri N, Shiraishi K, Yoshida S et al.. “Postoperative pyoderma gangrenosum in a patient with HLA-A26/B51 following hysterectomy and bilateral oophorectomy: a case report.” European journal of dermatology : EJD (2026). PMID: 41872086 ↗
Journal ArticleCited in: Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [44]
Diaz R, Allievi R, Cuniolo L et al.. “Post-Surgical Pyoderma Gangrenosum After Breast Cancer Surgery: A Multidisciplinary Case Report.” Current oncology (Toronto, Ont.) (2025). PMID: 41440229 ↗
Case Reports, Journal ArticleCited in: Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, Complications and Safety Problems in Pyoderma Gangrenosum - [45]
Tao LA, Cafro C, Rosser M et al.. “Successful revision surgery after postsurgical pyoderma gangrenosum following reduction mammaplasty: A case report.” JPRAS open (2026). PMID: 42542602 ↗
Case Reports, Journal ArticleCited in: Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Recognizable Phenotypes and Variants of Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, Complications and Safety Problems in Pyoderma Gangrenosum - [46]
Wu V, Lara-Corrales I, Sibbald C et al.. “Concurrent Hidradenitis Suppurativa and Pyoderma Gangrenosum in a Pediatric Cohort: A Retrospective Case Series.” Journal of cutaneous medicine and surgery (2025). PMID: 41189322 ↗
Journal ArticleCited in: Clinical Presentation: Lesion Evolution, Distribution, and Symptoms - [47]
Downey K, Zhang R, Ortega-Loayza AG. “Pyoderma Gangrenosum and Inflammatory Bowel Disease: Recent Insights into Epidemiology, Pathogenesis, and Therapeutic Approaches.” Journal of inflammation research (2025). PMID: 41255587 ↗
Journal Article, ReviewCited in: Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [48]
Gillespie J, Roland-McGowan J, Downey K et al.. “Recurrence after healing in pyoderma gangrenosum: a prospective registry-based cohort study.” EClinicalMedicine (2026). PMID: 42495104 ↗
Journal ArticleCited in: Clinical Presentation: Lesion Evolution, Distribution, and Symptoms, Healing, Recurrence, and Long-Term Follow-up - [49]
Gambichler T, Sanchez-Martinez E, Wichlacz J et al.. “Generalized Blastomycosis-Like Pyoderma in an Immunocompetent Patient.” International journal of dermatology (2026). PMID: 42165223 ↗
LetterCited in: Recognizable Phenotypes and Variants of Pyoderma Gangrenosum - [50]
Litsou E, Psychogios G, Saridi M et al.. “Ear, Nose, and Throat Manifestations in Inflammatory Bowel Diseases: A Systematic Review of the Clinical Spectrum.” Medicina (Kaunas, Lithuania) (2026). PMID: 42195197 ↗
Journal Article, Systematic ReviewCited in: Recognizable Phenotypes and Variants of Pyoderma Gangrenosum - [51]
Markowska M, Chętko Ł, Bień N et al.. “Primary Cutaneous B-Cell Lymphoma Imitating Pyoderma Gangrenosum: A Rare and Complex Diagnostic Challenge.” Journal of clinical medicine (2026). PMID: 41682819 ↗
Case Reports, Journal ArticleCited in: Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [52]
Yoshida K, Mikai H, Morisu S et al.. “A Case of Deep Cutaneous Fungal Infection Caused by Scedosporium apiospermum Mimicking Pyoderma Gangrenosum on the Bilateral Lower Legs in an Immunocompromised Patient.” International journal of dermatology (2026). PMID: 41524651 ↗
LetterCited in: Establishing the Diagnosis: Delphi Criteria, PARACELSUS, and Differential Diagnosis, Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [53]
Marzuk Z, Homsi Y, Moshiri AS et al.. “Pyoderma gangrenosum-like ulcer association in small vessel vasculitis (Vasculitis presenting as pyoderma gangrenosum-like ulcer).” The American journal of the medical sciences (2025). PMID: 40759365 ↗
Case Reports, Journal ArticleCited in: Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [54]
Tracy A, Morrissette K, Kroshinsky D. “Infantile Pyoderma Gangrenosum: A Rare and Challenging Case Presentation With an Updated Literature Review.” Pediatric dermatology (2025). PMID: 41263180 ↗
Journal Article, Case Reports, ReviewCited in: Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [55]
Murayama M, Tanaka Y, Yokose T et al.. “Sterile Nasal Septal Abscess in Ulcerative Colitis With Crypt Abscess-Like Neutrophilic Infiltration.” The Laryngoscope (2025). PMID: 40899420 ↗
Case Reports, Journal ArticleCited in: Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [56]
Howard-James C, Brennan C, Prior AR et al.. “Atypical waves: nonsporotrichoid Mycobacterium marinum skin infection in an immunocompromised scuba diver.” Skin health and disease (2025). PMID: 41312320 ↗
Case Reports, Journal ArticleCited in: Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [57]
Caddia G, Voulliaume D, Dettori L et al.. “Postsurgical Pyoderma Gangrenosum in Breast Surgery: An Updated Systematic Review, Takeaways, and the 6 Commandments.” Aesthetic surgery journal (2025). PMID: 40417872 ↗
Journal Article, Systematic ReviewCited in: Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [58]
Kusano M, Miura T, Hanami Y et al.. “Ulcerative and Hemorrhagic Bullous Pyoderma Gangrenosum Subsequently Developed Following IgA Vasculitis in a Patient With IgA-λ Multiple Myeloma.” The Journal of dermatology (2025). PMID: 40810462 ↗
LetterCited in: Biopsy, Microbiology, and Systemic Evaluation in Suspected Pyoderma Gangrenosum - [59]
Haddadin OM, Jacobson ME, Becker SL et al.. “Minimum dataset for treatment effectiveness in pyoderma gangrenosum for an international registry: an international multidisciplinary eDelphi consensus.” The British journal of dermatology (2026). PMID: 41784109 ↗
Journal Article, Consensus Statement, Systematic ReviewCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [60]
Jacobson ME, Rick JW, Gerbens LAA et al.. “A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative.” The British journal of dermatology (2024). PMID: 37952167 ↗
Journal Article, Consensus StatementCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [61]
Pimentel MA, Li MM, Noe MH et al.. “Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society.” The British journal of dermatology (2023). PMID: 36746554 ↗
Journal Article, Consensus StatementCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [62]
Lu JD, Hobbs MM, Huang WW et al.. “Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review.” The British journal of dermatology (2020). PMID: 32159849 ↗
Journal Article, Systematic ReviewCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [63]
Jacobson ME, Ng JW, Leon LM et al.. “Initial development and pragmatic clinical validation of a static disease severity instrument for pyoderma gangrenosum: Investigator Global Assessment for PG (IGAPg).” Journal of the American Academy of Dermatology (2026). PMID: 42067040 ↗
Journal ArticleCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [64]
Shire S, McFeeters J, Kim H et al.. “Validation of the Physician Global Assessment × Maximum Diameter (PGAMAX) as a severity assessment tool for pyoderma gangrenosum.” Journal of the American Academy of Dermatology (2025). PMID: 41354349 ↗
Journal ArticleCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [65]
Tobey T, Ortega-Loayza AG, Choe SI et al.. “Pyoderma gangrenosum refined elements for core item selection and evaluation (PRECISE-PG): a study protocol for reaching consensus on core outcome domain items in clinical trials of pyoderma gangrenosum.” Archives of dermatological research (2025). PMID: 39979653 ↗
Journal Article, Clinical Trial ProtocolCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [66]
Haddadin OM, Jacobson ME, Chen DM et al.. “Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative.” Archives of dermatological research (2023). PMID: 37755505 ↗
Journal ArticleCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [67]
Rick J, Gould LJ, Marzano AV et al.. “The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum.” Archives of dermatological research (2022). PMID: 36305958 ↗
Journal ArticleCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [68]
Haag C, Hansen T, Hajar T et al.. “Comparison of Three Diagnostic Frameworks for Pyoderma Gangrenosum.” The Journal of investigative dermatology (2020). PMID: 32445742 ↗
Comparative Study, Journal Article, Research Support, Non-U.S. Gov'tCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [69]
Kaur M, Diaz MJ, Anthony M et al.. “Treatments for Pyoderma Gangrenosum: A Systematic Review and Single-Arm Meta-Analysis of Systemic Therapies.” International wound journal (2025). PMID: 40740034 ↗
Journal Article, Meta-Analysis, Systematic ReviewCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum, Local Control of Limited Pyoderma Gangrenosum, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [70]
Cascio Ingurgio R, Alfano A, Gargiulo L et al.. “Using Biologics to Reduce Long-Term Corticosteroid Use in Pyoderma Gangrenosum: Real-World Evidence From Two Centres.” The Australasian journal of dermatology (2025). PMID: 40421919 ↗
Journal ArticleCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [71]
Haroon A, Gillespie J, Roland-McGowan J et al.. “Local wound care management for pyoderma gangrenosum.” International wound journal (2024). PMID: 39557450 ↗
Letter, Systematic ReviewCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum, Local Control of Limited Pyoderma Gangrenosum - [72]
Bar D, Baum S, Druyan A et al.. “Clinical course and prognostic disparities of pyoderma gangrenosum based on underlying disease: A long-term comparative study in 124 patients.” Annales de dermatologie et de venereologie (2025). PMID: 40199040 ↗
Journal Article, Comparative StudyCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [73]
Lin RR, Maskan Bermudez N, Burke OM et al.. “Clinical characteristics and outcomes of genital pyoderma gangrenosum - A systematic review.” Journal of the American Academy of Dermatology (2025). PMID: 39909344 ↗
Journal ArticleCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum - [74]
Hasselmann DO, Bens G, Tilgen W et al.. “Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature.” Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2007). PMID: 17610605 ↗
Case Reports, Journal Article, ReviewCited in: Measuring Severity and Treatment Response in Pyoderma Gangrenosum, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [75]
Donnelly H, Boffa MJ. “Topical treatment of pyoderma gangrenosum: A systematic review.” Indian journal of dermatology, venereology and leprology (2025). PMID: 39152834 ↗
Journal Article, Systematic ReviewCited in: Local Control of Limited Pyoderma Gangrenosum - [76]
Shojaei D, Zabihi H, Al-Dehneem R et al.. “Emerging Topical Therapies for Pyoderma Gangrenosum: An Evidence-Based Review.” Journal of cutaneous medicine and surgery (2024). PMID: 39367789 ↗
LetterCited in: Local Control of Limited Pyoderma Gangrenosum - [77]
Keum H, Zhivov EV, Ortega-Loayza AG. “Updates in innovation of the treatment of pyoderma gangrenosum.” Expert review of clinical pharmacology (2025). PMID: 39720859 ↗
Journal Article, ReviewCited in: Local Control of Limited Pyoderma Gangrenosum - [78]
Tan MG, Tolkachjov SN. “Treatment of Pyoderma Gangrenosum.” Dermatologic clinics (2023). PMID: 38423680 ↗
Journal Article, ReviewCited in: Local Control of Limited Pyoderma Gangrenosum - [79]
Werner M, Stromer W, Hüning S et al.. “Supportive pain therapy in dermatology.” Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2025). PMID: 40401308 ↗
Journal Article, ReviewCited in: Local Control of Limited Pyoderma Gangrenosum - [80]
Bar D, Beberashvili I. “Assessing the role of wound debridement in pyoderma gangrenosum-A retrospective cohort study.” Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society (2024). PMID: 39262283 ↗
Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum - [81]
Akoğlu G, Demiriz M, Yılmaz KB. “Pyoderma Gangrenosum: A Nightmare for Breast Surgery-Two Case Reports.” European journal of breast health (2025). PMID: 39744929 ↗
Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum - [82]
Pluta NA, Kemp TL, Rivard SC. “Treatment Considerations for Pyoderma Gangrenosum After Reduction Mammoplasty in an Unsuspecting Patient Demographic.” Plastic and reconstructive surgery. Global open (2025). PMID: 39802275 ↗
Case Reports, Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy - [83]
Karch JL, Bradley KE, Moore AM et al.. “A retrospective study on the demographics and epidemiology of pyoderma gangrenosum: Insights from a single-center analysis.” JAAD international (2025). PMID: 40677729 ↗
Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum - [84]
Bardazzi F, Maltoni L, Clarizio G et al.. “Pyoderma Gangrenosum: A Retrospective Case Series of 44 Patients.” Dermatology practical & conceptual (2024). PMID: 39652952 ↗
Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum - [85]
Moltrasio C, Romagnuolo M, Tavoletti G et al.. “Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment.” Seminars in immunopathology (2025). PMID: 41128863 ↗
Journal Article, Review, Research Support, Non-U.S. Gov'tCited in: Local Control of Limited Pyoderma Gangrenosum, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum, Complications and Safety Problems in Pyoderma Gangrenosum - [86]
Bauerle WB, O'Connell JM, Hoy O et al.. “Larval Debridement Therapy for Management of Postsurgical Wounds in the Setting of Pyoderma Gangrenosum.” Plastic and reconstructive surgery. Global open (2025). PMID: 40765687 ↗
Case Reports, Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum, Surgery, Debridement, and Reconstruction: Avoiding Pathergy - [87]
Yan A, Gallardo M, Savu A et al.. “Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome: a single-institution case series with a focus on management.” Archives of dermatological research (2024). PMID: 38878169 ↗
Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum, Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [88]
Derstenfeld A, Meunier RS, Bouchard J et al.. “Multiple Pyoderma Gangrenosum Overlying AV Fistula Treated With Colchicine: A Case Report.” Canadian journal of kidney health and disease (2024). PMID: 39371934 ↗
Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum - [89]
Perry NJ, Wang S, Smith R et al.. “Rapidly Progressive Idiopathic Pyoderma Gangrenosum in a Pediatric Patient Successfully Treated With Infliximab.” Pediatric dermatology (2024). PMID: 39586834 ↗
Case Reports, Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum - [90]
Mastronardi M, Cavalcanti E, Labarile N et al.. “Pyoderma gangrenosum in ulcerative colitis patient treated with vedolizumab: adsorptive granulocyte/monocyte apheresis as a new therapeutic option refractory cases - a case report and literature review.” Therapeutic advances in chronic disease (2023). PMID: 37928629 ↗
Case Reports, Journal ArticleCited in: Local Control of Limited Pyoderma Gangrenosum - [91]
Partridge ACR, Bai JW, Rosen CF et al.. “Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials.” The British journal of dermatology (2018). PMID: 29478243 ↗
Journal Article, Systematic ReviewCited in: Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [92]
Tan B, Chen M, Hu X et al.. “Pyoderma Gangrenosum with Biological Agents Therapy: A Systematic Review.” Clinical, cosmetic and investigational dermatology (2025). PMID: 41425114 ↗
Journal Article, ReviewCited in: Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum, Complications and Safety Problems in Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [93]
Feldman SR, Lacy FA, Huang WW. “The safety of treatments used in pyoderma gangrenosum.” Expert opinion on drug safety (2017). PMID: 29065721 ↗
Journal Article, ReviewCited in: Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [94]
Olabi B, Kim C, Dubois A et al.. “Implementation of biologic treatments for pyoderma gangrenosum through a service development framework.” Clinical and experimental dermatology (2026). PMID: 42228928 ↗
Journal ArticleCited in: Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [95]
Dai A, Kim SJ. “Systemic calcineurin inhibitors tacrolimus and voclosporin: A review of off-label dermatologic uses.” Journal of the American Academy of Dermatology (2023). PMID: 37307993 ↗
Journal Article, ReviewCited in: Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [96]
Liwei W, Yihong Q, Fei T et al.. “Secukinumab treatment in a pediatric patient with corticosteroid-intolerant pyoderma gangrenosum: a case report.” Frontiers in medicine (2025). PMID: 41114019 ↗
Case Reports, Journal ArticleCited in: Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [97]
Ge G, Zhan L, Huang M et al.. “Case Report: Treatment of facial pyoderma gangrenosum with Upadacitinib.” Frontiers in medicine (2025). PMID: 41080966 ↗
Case Reports, Journal ArticleCited in: Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum - [98]
Fousekis F, Ronicke M, Sollfrank L et al.. “Successful treatment of severe retroauricular pyoderma gangrenosum with upadacitinib in a patient with Crohn's disease and a history of cerebral venous sinus thrombosis.” Therapeutic advances in gastroenterology (2026). PMID: 41743373 ↗
Case Reports, Journal ArticleCited in: Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum, Complications and Safety Problems in Pyoderma Gangrenosum - [99]
Chêne L, Hubiche T, De Guillebon JM et al.. “TNF Inhibitor Therapy in Corticosteroid-Resistant or -Dependent Pediatric Neutrophilic Dermatosis.” Pediatric dermatology (2025). PMID: 41185550 ↗
Journal Article, Case ReportsCited in: Systemic Immunosuppression and Biologic Therapy for Pyoderma Gangrenosum, PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [100]
Dahy AA, Hassan RM, Altramsy A et al.. “Outcomes and Risk Factors of Pyoderma Gangrenosum After Reduction Mammoplasty: A Systematic Review of the Literature and Case Report.” Aesthetic plastic surgery (2025). PMID: 40389731 ↗
Journal Article, Systematic Review, Case ReportsCited in: Surgery, Debridement, and Reconstruction: Avoiding Pathergy - [101]
Marcoval J, Muntaner-Virgili C, Boronat-Cucarull J et al.. “Pyoderma Gangrenosum of the Breast: A Diagnostic Challenge.” Breast care (Basel, Switzerland) (2025). PMID: 40547186 ↗
Journal ArticleCited in: Surgery, Debridement, and Reconstruction: Avoiding Pathergy - [102]
Lauder AP, Nwiloh A, Eximond M et al.. “Resolution of Pyoderma Gangrenosum During Adjuvant Breast Cancer Therapy.” Journal of clinical medicine (2025). PMID: 40004850 ↗
Case Reports, Journal ArticleCited in: Surgery, Debridement, and Reconstruction: Avoiding Pathergy - [103]
Ball GD, Romanelli S, Bodner JM et al.. “Pyoderma Gangrenosum in Pregnancy: A Systematic Review of Clinical Characteristics, Treatment Outcomes, and Maternofetal Implications.” Journal of drugs in dermatology : JDD (2025). PMID: 40627582 ↗
Journal Article, Systematic ReviewCited in: PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [104]
Norouzi-Barough L, Biglari S, Sherkat R et al.. “A Systematic Review of Mendelian Pyoderma Gangrenosum: Clinical and Genetic Characteristics in 120 Published Patients.” Experimental dermatology (2025). PMID: 40329681 ↗
Systematic Review, Journal ArticleCited in: PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [105]
Biswas D, Saha D, Patra S et al.. “Recurrent pyoderma gangrenosum-like ulcers in a child revealing leucocyte adhesion deficiency type I.” Clinical and experimental dermatology (2026). PMID: 41664479 ↗
Journal ArticleCited in: PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings, Healing, Recurrence, and Long-Term Follow-up - [106]
Malhi K, Singh S, Vignesh P et al.. “Unusual Cutaneous and Mucosal Manifestations of Neonatal Inflammatory Skin and Bowel Disease Type 1 due to a Novel Homozygous ADAM17 Mutation.” Pediatric dermatology (2026). PMID: 42015567 ↗
Case Reports, Journal ArticleCited in: PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [107]
da Rosa G, Granja BV, Azevedo F et al.. “Pyoderma Gangrenosum-Associated Autoinflammatory Syndrome With Skin Abscesses: Successful Treatment With Anti-Interleukin 1 Therapy.” The Journal of rheumatology (2025). PMID: 40374517 ↗
Journal ArticleCited in: PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [108]
Burke OM, Lin R, Elman SA et al.. “Genetic Basis of Autoinflammatory Skin Diseases. Part I. Genetic Pathways of Complex Autoinflammatory Skin Diseases.” Journal of the American Academy of Dermatology (2025). PMID: 40543672 ↗
Journal Article, ReviewCited in: PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [109]
Norouzi-Barough L, Olyaei NA, Carapito R et al.. “A novel ITGB2 variant in a patient with severe recurrent pyoderma gangrenosum-like lesions and underlying leukocyte adhesion deficiency type I: case report and literature review.” Archives of dermatological research (2025). PMID: 40195196 ↗
Journal Article, Case Reports, ReviewCited in: PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [110]
Qin Q, Cao C, Liang J et al.. “Case Report: Diagnostic difficulties, treatment, and association of the MEFV E148Q variant in a patient with PASH syndrome.” Frontiers in medicine (2025). PMID: 40861239 ↗
Case Reports, Journal ArticleCited in: PG in Pregnancy, Childhood, Peristomal Sites, and Other High-Risk Settings - [111]
Bostwick S, Erickson K, Ortega Loayza AG. “The clinical significance of quality of life in pyoderma gangrenosum.” The British journal of dermatology (2026). PMID: 41001828 ↗
Journal ArticleCited in: Complications and Safety Problems in Pyoderma Gangrenosum - [112]
Thakker S, Patel D, Elman SA. “Longitudinal cardiovascular outcomes in pyoderma gangrenosum: A propensity-matched TriNetX cohort study.” Journal of the American Academy of Dermatology (2025). PMID: 40962188 ↗
Journal ArticleCited in: Complications and Safety Problems in Pyoderma Gangrenosum - [113]
Tsilimpotis D, Kyriakou G, Biedermann L et al.. “Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.” Inflammatory bowel diseases (2026). PMID: 41136229 ↗
Journal Article, ReviewCited in: Complications and Safety Problems in Pyoderma Gangrenosum - [114]
Kerniss H, Olbrich H, Curman P et al.. “Pyoderma gangrenosum is associated with excess incident major atherothrombotic events.” Atherosclerosis (2026). PMID: 42263577 ↗
Journal ArticleCited in: Complications and Safety Problems in Pyoderma Gangrenosum - [115]
Kerniss H, Curman P, Olbrich H et al.. “Incident atrial fibrillation and pyoderma gangrenosum: long-term thromboembolic, heart failure, and mortality risk.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 42545495 ↗
Journal ArticleCited in: Complications and Safety Problems in Pyoderma Gangrenosum - [116]
Vague M, Shea M, Kumar I et al.. “Laser Therapy in the Treatment of Scarring Secondary to Pyoderma Gangrenosum: A Case Series.” Lasers in surgery and medicine (2026). PMID: 41845874 ↗
Case Reports, Journal ArticleCited in: Complications and Safety Problems in Pyoderma Gangrenosum, Healing, Recurrence, and Long-Term Follow-up - [117]
Voica C, Cercel DA, Safta MS et al.. “Carotid Pseudoaneurysm Repair in a Patient with Myeloproliferative Disorder Complicated by Contralateral Stroke, Graft Thrombosis, Pyoderma Gangrenosum, and Superinfection: A Case Report.” Journal of clinical medicine (2026). PMID: 41977069 ↗
Case Reports, Journal ArticleCited in: Complications and Safety Problems in Pyoderma Gangrenosum - [118]
Yang Y, Xu Z, Chen W et al.. “Hematologic disease and chronic alcohol use independently predict poor prognosis in pyoderma gangrenosum.” JAAD international (2025). PMID: 41393355 ↗
Journal ArticleCited in: Healing, Recurrence, and Long-Term Follow-up - [119]
Bai JQA, Wen S, Toy J et al.. “Hyperbaric Oxygen Therapy for the Treatment of Pyoderma Gangrenosum: A Systematic Review.” Journal of cutaneous medicine and surgery (2026). PMID: 41910076 ↗
LetterCited in: Healing, Recurrence, and Long-Term Follow-up